Altered amantadine effects after repetitive treatment for l-dopa-induced involuntary movements in a rat model of Parkinson’s disease

[1]  F. Manfredsson,et al.  The multimodal serotonin compound Vilazodone alone, but not combined with the glutamate antagonist Amantadine, reduces l-DOPA-induced dyskinesia in hemiparkinsonian rats , 2022, Pharmacology Biochemistry and Behavior.

[2]  C. Tanner,et al.  Amantadine delayed release/extended release capsules significantly reduce OFF time in Parkinson’s disease , 2022, NPJ Parkinson's disease.

[3]  O. Rascol,et al.  Immediate-release/extended-release amantadine (OS320) to treat Parkinson's disease with levodopa-induced dyskinesia: Analysis of the randomized, controlled ALLAY-LID studies. , 2022, Parkinsonism & related disorders.

[4]  M. Tomiyama,et al.  Morphological and Functional Changes of Striatal Neurons with L‐dopa‐induced Dyskinesia , 2021, Neurology and Clinical Neuroscience.

[5]  W. Poewe,et al.  Amantadine in the treatment of Parkinson's disease and other movement disorders , 2021, The Lancet Neurology.

[6]  N. Inagaki,et al.  Shootin1a-mediated actin-adhesion coupling generates force to trigger structural plasticity of dendritic spines. , 2021, Cell reports.

[7]  P. Riederer,et al.  Amantadine: reappraisal of the timeless diamond—target updates and novel therapeutic potentials , 2021, Journal of Neural Transmission.

[8]  N. Ichinohe,et al.  GABA storage and release in the medial globus pallidus in L-DOPA-induced dyskinesia priming , 2020, Neurobiology of Disease.

[9]  J. Kasahara,et al.  Intrastriatal Memantine Infusion Dampens Levodopa-Induced Dyskinesia and Motor Deficits in a Mouse Model of Hemiparkinsonism , 2019, Front. Neurol..

[10]  S. Ueno,et al.  Zonisamide Enhances Motor Effects of Levodopa, Not of Apomorphine, in a Rat Model of Parkinson's Disease , 2018, Parkinson's disease.

[11]  A. Crossman,et al.  Animal models of l‐dopa‐induced dyskinesia in Parkinson's disease , 2018, Movement disorders : official journal of the Movement Disorder Society.

[12]  C. Adler,et al.  Parkinson's Patients with Dyskinesia Switched from Immediate Release Amantadine to Open‐label ADS‐5102 , 2018, Movement disorders clinical practice.

[13]  T. Shirao,et al.  The role of drebrin in dendritic spines , 2017, Molecular and Cellular Neuroscience.

[14]  S. Ueno,et al.  Levodopa treatment and dendritic spine pathology , 2017, Movement disorders : official journal of the Movement Disorder Society.

[15]  W. Oertel,et al.  Randomized, placebo‐controlled trial of ADS‐5102 (amantadine) extended‐release capsules for levodopa‐induced dyskinesia in Parkinson's disease (EASE LID 3) , 2017, Movement disorders : official journal of the Movement Disorder Society.

[16]  C. Tanner,et al.  ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial , 2017, JAMA neurology.

[17]  H. Widner,et al.  Memantine and reduced time with dyskinesia in Parkinson′s Disease , 2016, Acta neurologica Scandinavica.

[18]  M. Bortolanza,et al.  Antidyskinetic Effect of 7-Nitroindazole and Sodium Nitroprusside Associated with Amantadine in a Rat Model of Parkinson’s Disease , 2016, Neurotoxicity Research.

[19]  C. Tanner,et al.  Amantadine extended release for levodopa‐induced dyskinesia in Parkinson's disease (EASED Study) , 2015, Movement disorders : official journal of the Movement Disorder Society.

[20]  M. Collu,et al.  Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson’s disease , 2014, Neuroscience.

[21]  J. Yamada,et al.  Morphologic changes of dendritic spines of striatal neurons in the levodopa‐induced dyskinesia model , 2014, Movement disorders : official journal of the Movement Disorder Society.

[22]  A. Destée,et al.  Withdrawing amantadine in dyskinetic patients with Parkinson disease , 2014, Neurology.

[23]  J. Yamada,et al.  Drebrin immunoreactivity in the striatum of a rat model of levodopa‐induced dyskinesia , 2013, Neuropathology : official journal of the Japanese Society of Neuropathology.

[24]  A. P. Valle,et al.  Unexpected Improvement in Levodopa‐Induced Dyskinesia and On‐Off Phenomena After Introduction of Memantine for Treatment of Parkinson's Disease Dementia , 2013, Journal of the American Geriatrics Society.

[25]  P. Ravenscroft,et al.  Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.

[26]  M. Morari,et al.  Amantadine attenuates levodopa‐induced dyskinesia in mice and rats preventing the accompanying rise in nigral GABA levels , 2011, Journal of neurochemistry.

[27]  K. Hisanaga,et al.  Amantadine for Dyskinesias in Parkinson's Disease: A Randomized Controlled Trial , 2010, PloS one.

[28]  E. Wolf,et al.  Long‐term antidyskinetic efficacy of amantadine in Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.

[29]  S. Varanese,et al.  NMDA antagonist memantine improves levodopa‐induced dyskinesias and “On‐off” phenomena in Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.

[30]  K. Svoboda,et al.  Experience-dependent structural synaptic plasticity in the mammalian brain , 2009, Nature Reviews Neuroscience.

[31]  J. Jankovic.  Parkinson’s disease: clinical features and diagnosis , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[32]  M. Cenci,et al.  Ratings of L‐DOPA‐Induced Dyskinesia in the Unilateral 6‐OHDA Lesion Model of Parkinson's Disease in Rats and Mice , 2007, Current protocols in neuroscience.

[33]  W. Danysz,et al.  Modulation of l-DOPA-induced abnormal involuntary movements by clinically tested compounds: Further validation of the rat dyskinesia model , 2007, Behavioural Brain Research.

[34]  Fabrizio Stocchi,et al.  Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. , 2005, Archives of neurology.

[35]  C. Aoki,et al.  Drebrin A is a postsynaptic protein that localizes in vivo to the submembranous surface of dendritic sites forming excitatory synapses , 2005, The Journal of comparative neurology.

[36]  M. Murer,et al.  Behavioral sensitization to different dopamine agonists in a parkinsonian rodent model of drug-induced dyskinesias , 2004, Behavioural Brain Research.

[37]  E. Bézard,et al.  Levetiracetam Potentiates the Antidyskinetic Action of Amantadine in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-Lesioned Primate Model of Parkinson's Disease , 2004, Journal of Pharmacology and Experimental Therapeutics.

[38]  T. Suda,et al.  Amantadine increases l-DOPA-derived extracellular dopamine in the striatum of 6-hydroxydopamine-lesioned rats , 2003, Brain Research.

[39]  N. Wierup,et al.  Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease , 2002, The European journal of neuroscience.

[40]  W. Poewe,et al.  Beneficial effects of amantadine on L‐dopa‐induced dyskinesias in Parkinson's disease , 2000, Movement disorders : official journal of the Movement Disorder Society.

[41]  S. Konitsiotis,et al.  Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. , 1999, Archives of neurology.

[42]  T. Suda,et al.  Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. , 1999, Neuroreport.

[43]  T. Chase,et al.  Amantadine reduces levodopa‐induced dyskinesias in parkinsonian monkeys , 1998, Movement disorders : official journal of the Movement Disorder Society.

[44]  A. Björklund,et al.  L‐DOPA‐induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin‐ and glutamic acid decarboxylase mRNA , 1998, The European journal of neuroscience.

[45]  J. Brotchie,et al.  Characterization of Enhanced Behavioral Responses tol-DOPA Following Repeated Administration in the 6-Hydroxydopamine-Lesioned Rat Model of Parkinson's Disease , 1998, Experimental Neurology.

[46]  K. Shannon,et al.  Amantadine and motor fluctuations in chronic Parkinson's disease. , 1987, Clinical neuropharmacology.

[47]  M. Delong,et al.  Parkinson's Disease Therapeutics: New Developments and Challenges Since the Introduction of Levodopa , 2012, Neuropsychopharmacology.

[48]  T. Archer,et al.  Co-administration of memantine and amantadine with sub/suprathreshold doses of L-Dopa restores motor behaviour of MPTP-treated mice , 2009, Journal of Neural Transmission.

[49]  M. Onofrj,et al.  Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. , 2004, Journal of neurology, neurosurgery, and psychiatry.